Eris Lifesciences Limited reported a strong performance for the second quarter of FY26, with a healthy rise in profitability and steady revenue growth.
The company’s net profit surged 31.2% year-on-year to ₹120 crore, compared to ₹92 crore in the same quarter last year. Revenue increased 6.3% to ₹792 crore, up from ₹746 crore in Q2FY25, reflecting consistent growth across key therapeutic segments.
Operating performance also remained robust, with EBITDA rising 7% YoY to ₹288 crore, against ₹269 crore in the previous year. The company’s EBITDA margin expanded to 36.3%, compared to 33% last year, driven by improved operational efficiency and a better product mix.
Disclaimer: This article is for informational purposes only. It is not intended to be investment advice or a recommendation to buy or sell any stock. Readers are advised to consult their financial advisor before making any investment decisions.
